Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-Term Valacyclovir Therapy.
Research output: Contribution to journal › Article
Abstract
Despite the proven efficacy of acyclovir therapy, herpes simplex encephalitis (HSE) continues to cause substantial morbidity and mortality. Among patients with HSE treated with acyclovir (ACV), the mortality rate is approximately 14-19%. Among survivors, 45-60% have neuropsychological sequelae at 1 year. Thus, improving therapeutic approaches to HSE remains a high priority.
Details
| Authors | |
|---|---|
| Organisations | |
| Research areas and keywords | Subject classification (UKÄ) – MANDATORY
|
| Original language | English |
|---|---|
| Pages (from-to) | 683-691 |
| Journal | Clinical Infectious Diseases |
| Volume | 61 |
| Issue number | 5 |
| Publication status | Published - 2015 |
| Publication category | Research |
| Peer-reviewed | Yes |
Bibliographic note
The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Division of Infection Medicine (SUS) (013008000)
